Abstract
• Commendation of LMO2′s role: Wang et al.'s study demonstrates LMO2 as a promising immunotherapy marker and tumor suppressor in clear cell renal cell carcinoma (ccRCC), supported by multi-omics integration and mechanistic insights into the ZC3H13-m6A-LMO2-GATA2-BEX1-NF-κB axis. • Methodological enhancements suggested: Implement rigorous statistical corrections (e.g., Bonferroni or FDR for TCGA data) and adopt immunocompetent models (e.g., syngeneic ccRCC grafts in C57BL/6 mice) to improve robustness and translational relevance. • Direct validation required: Verify protein interactions (e.g., LMO2-GATA2 binding via co-immunoprecipitation) and m6A modification sites in LMO2 mRNA to strengthen mechanistic claims. • Functional testing for immunotherapy: Conduct in vitro co-culture or in vivo immunotherapy response models to causally link LMO2 to immune regulation and validate its biomarker potential. • Future innovation pathways: Explore epigenetic layers (e.g., m1A or m5C modifications via nanopore sequencing), apply single-cell multi-omics, and advance preclinical studies combining LMO2-targeted therapies with immune checkpoint inhibitors.